Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Featured Products > Oncology Research > Renal Cell Carcinoma
Renal Cell Carcinoma Reagents — VEGFR, PD-L1, CA9, CD70, HIF | abinScience

Renal Cell Carcinoma Research Reagents

RCC, particularly clear cell (ccRCC), is driven by VHL loss and HIF pathway activation leading to VEGF overexpression. First-line therapy combines VEGFR TKIs with immune checkpoint inhibitors. abinScience provides reagents for VEGF/VEGFR, PD-1/PD-L1/CTLA-4, HIF/VHL, CA9/CAIX, CD70, and next-generation checkpoints (LAG-3, TIGIT, TIM-3). RUO

Key Biomarkers & Targets

VEGF / VEGFR
Angiogenesis Axis
Central pathway in ccRCC; sunitinib, pazopanib, cabozantinib, and bevacizumab all target the VEGF axis. 260+ combined products.
Antibodies • Proteins • Biosimilars
PD-1 / PD-L1 / CTLA-4
Checkpoint Combinations
Nivolumab + ipilimumab and pembrolizumab + axitinib define first-line ccRCC treatment. 400+ combined reagents.
Antibodies • Proteins • Biosimilars
HIF / VHL
Hypoxia Pathway
VHL loss drives HIF-2α stabilization in ccRCC; belzutifan (HIF-2α inhibitor) is first-in-class. 40 combined antibodies and proteins.
Antibodies • Proteins
CA9 / CAIX
Carbonic Anhydrase IX
HIF target gene product; ccRCC biomarker and emerging ADC target. Antibodies with FCM and ELISA validation. 40+ products.
Antibodies • Proteins
CD70
TNFSF7
Overexpressed in ccRCC; ADC target (cusatuzumab-based approaches). 32 antibodies and biosimilar proteins.
Antibodies • Biosimilars
LAG-3 / TIGIT / TIM-3
Next-Gen Checkpoints
Under active investigation as combination partners with PD-1 blockade in RCC. 125+ combined products.
Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for RCC

VHL-HIF-VEGF Pathway DepthVHL, HIF-1α/2α, VEGF-A, VEGFR1/2, and CA9 antibodies covering the entire ccRCC driver axis from genetic loss to effector targets.
Multi-Checkpoint PortfolioPD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3 for studying combination immunotherapy strategies and resistance in RCC.
Emerging ADC TargetsCD70, CA9/CAIX, and TROP2 antibodies and recombinant proteins for kidney cancer-specific ADC and radioimmunotherapy development.
Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

  1. VHL-HIF pathway characterization: Profile VHL loss, HIF-2α stabilization, and downstream CA9/VEGF expression in ccRCC cell lines and patient tissue to study belzutifan mechanism of action.
  2. Anti-angiogenic drug resistance: Use VEGFR, MET, AXL, and FGFR antibodies to characterize compensatory RTK signaling as resistance mechanisms to sunitinib and cabozantinib.
  3. IO combination biomarkers: Profile PD-L1 + LAG-3 + TIGIT co-expression on tumor and immune cells to identify rational dual-checkpoint blockade combinations in RCC.
  4. ccRCC diagnostic confirmation: CA9, PAX8, and CD10 antibodies available for RCC research. See product pages for validated applications.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you carry CA9/CAIX antibodies for RCC IHC?

Anti-CA9 monoclonal antibodies with FC and ELISA validation (e.g., clones SAA0152, SAA0475). Research-grade girentuximab biosimilar with ELISA and FACS validation also available.

Which VHL/HIF pathway antibodies do you offer?

Anti-VHL and HIF pathway antibodies, plus recombinant HIF proteins available. See product pages for validated applications.

Do you have CD70 reagents for ADC development?

Anti-CD70 antibodies and research-grade biosimilar proteins available. See product pages for validated applications.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.

248 product results for "Renal Cell Carcinoma"

Options+
Options
Confirm
  • Product types
    0 selected
    Proteins (36)
    Research Biosimiliar (1)
    Antibodies (105)
    Biosimilars (2)
    Research Biosimilar (104)
  • Expression system
    0 selected
    Insect Cells (1)
    Mammalian Cells (120)
    E. coli (20)
  • Target
    0 selected
    EPAS1 (1)
    CD274/PD-L1 & CD3E (1)
    CD274/PD-L1 & TGFBR2 (1)
    RICTOR (1)
    CD309/VEGFR2 (1)
    VHL (1)
    CD274/PD-L1 & CD28 & CD152/CTLA4 (1)
    CD274/PD-L1 (59)
    CD274/PD-L1/B7-H1 (1)
    CA9 (11)
    C3 & C4B & VEGFA (1)
    CD152/CTLA4 & CD274/PD-L1 (1)
    CD274/PD-L1 & SLT-Ia (1)
    CD10/MME (6)
    Vascular endothelial growth factor A (1)
    CD309/VEGFR-2 (22)
    CD274/PD-L1 & CD47/MER6 (1)
    CD366/TIM-3 & CD274/PD-L1 (1)
    Fluorescein & CD274/PD-L1 (1)
    PROK1/EG-VEGF (1)
    VEGF-C/VEGF-D (1)
    CD140b/PDGFRB (11)
    PAX8 (1)
    FGF2/bFGF & VEGFA (1)
    CD19 & PD-L1 & CD3E & CD137 (1)
    VPF (1)
    CD274/PD-L1 & CD134/OX40 (1)
    CD137/4-1BB & CD274/PD-L1 (3)
    VBP1 (1)
    LAMTOR5/HBXIP (1)
    PDL1 & VEGF (1)
    CD274/PD-L1 & CD279/PD-1 (1)
    VEGFA (31)
    USP20 (1)
    HIF1AN (2)
    DEPTOR (1)
    VEGF (1)
    MTOR (1)
    VIM/Vimentin (10)
    VEGFA & ANG-2 (3)
    CD140a/PDGFRA (14)
    ERAP1 (1)
    TIGIT & CD274/PD-L1 (1)
    CD274/PD-L1 & CD28 (1)
    EGFR & CD3E & PD-L1 & 4-1BB (1)
    CD274/PD-L1 & VEGFA (1)
    Vascular permeability factor (1)
    CD274/PD-L1 & CD152/CTLA4 (1)
    LAMTOR4 (1)
    HIF2A/EPAS1 (2)
    CD274/PD-L1 & TGFBR2/TGFR-2 (1)
    ACVRL1/ALK-1 & VEGFA (1)
    VEGFB (5)
    PDGFC (3)
    CD279/PD-1 & CD274/PD-L1 (1)
    DLL4 & VEGFA (2)
    VEGFA & CD279/PD-1 (1)
    VEGF-A (1)
    HIF1A (1)
    CD47/MER6 & CD274/PD-L1 (2)
    CD274/PD-L1 & CD137/TNFRSF9 (1)
    VEGFC (1)
    VSIR/VISTA & CD274/PD-L1 (1)
    VEGFA & ANGPT2/ANG-2 (1)
    CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)
    FLT1/VEGFR1 & CD274/PD-L1 (1)
  • Species
    0 selected
    Human (126)
    Mus musculus (Mouse) (3)
    Mouse (10)
    Homo sapiens (Human) (9)
    Felis catus (Cat) (2)
    Tupaia chinensis (1)
  • Applications
    0 selected
    Bioactivity: FACS (98)
    IHC (23)
    Functional assay (106)
    SDS-PAGE (36)
    Research in vivo (106)
    FCM (64)
    SPR (2)
    Immunogen (36)
    Bioactivity testing in progress (21)
    FACS (3)
    ELISA (197)
    Functional assay (3)
    Neutralization (2)
    FuncS (12)
    WB (66)
  • Reactivity
    0 selected
    Tupaia chinensis (1)
    B7-H1 / PD-L1 / CD274 (1)
    Rat (5)
    Mouse (25)
    Homo sapiens (Human) (1)
    CD309/KDR/VEGFR-2 (1)
    Human (73)
    Bovine (2)
  • Host species
    0 selected
    Human (91)
    Rabbit (13)
    Rat (9)
    Chimeric (4)
    Mouse (58)
    Alpaca (2)
    Humanized (29)
  • Clonality
    0 selected
    Polyclonal (13)
    Monoclonal (191)
  • Conjugate
    0 selected
    PerCP (11)
    PE (21)
    Unconjugated (155)
    FITC (10)

Quick access

Contact Us

  • +86-27-65523339

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only